Filtered By:
Condition: Polymyositis

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 420 results found since Jan 2013.

Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis
Conclusions: Anti-NT5c1A has moderate sensitivity and high specificity for sIBM using ALBIA. The presence of anti-NT5c1A antibodies may be associated with muscle weakness. Anti-NT5c1A antibodies were not associated with a specific IIF staining pattern, hence screening using HEp-2 substrate is unlikely to be a useful predictor for presence of these autoantibodies. Introduction Sporadic Inclusion Body Myositis (sIBM) is one subset of idiopathic inflammatory myopathies (IIM) that is characterized by a clinical presentation of asymmetrical muscle involvement, predominantly affecting the long finger flexors, quadriceps mu...
Source: Frontiers in Immunology - April 8, 2019 Category: Allergy & Immunology Source Type: research

Cardiac Manifestations in Idiopathic Inflammatory Myopathies: An Overview
Idiopathic inflammatory myopathies are a group of autoimmune diseases that are characterized by muscle inflammation resulting in elevated muscle enzyme release and distinctive biopsy findings. This group of conditions includes polymyositis, dermatomyositis, inclusion body myositis, and necrotizing autoimmune myopathy. Although they have many similarities, the inflammatory myopathies differ in their clinical, pathological, and treatment realms. Extramuscular manifestations may involve many organs that include the skin, joints, heart, lungs, and gastrointestinal tract. Cardiovascular involvement is one of the leading causes ...
Source: Cardiology in Review - April 6, 2019 Category: Cardiology Tags: Review Articles Source Type: research

18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications
Conclusion 18F-FDG PET/CT does not appear to be useful in cancer screening for AIM patients compared with conventional screening and carries potential harms associated with follow-up investigations. The risk of cancer in AIM differs by myositis-specific antibodies-defined subsets and cancer screening is likely to be indicated only in high-risk patients, particularly DM. These results, replicated in larger, multicentered studies, may carry significant consequences for optimal management of AIM and health resource utilization.
Source: Nuclear Medicine Communications - March 16, 2019 Category: Nuclear Medicine Tags: ORIGINAL ARTICLES Source Type: research

Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology
Conclusion Rhabdomyolysis-like features, positive anti-AChR antibody without decremental RNS responses, and PD-L1 overexpression are possible characteristics shared by ICI-induced IM. Frequent thymoma association in patients with idiopathic IM and MG may suggest thymoma-related immunopathogenic mechanisms, including dysregulation of the immune checkpoint pathway.
Source: Neurology Neuroimmunology and Neuroinflammation - December 24, 2018 Category: Neurology Authors: Uchio, N., Taira, K., Ikenaga, C., Kadoya, M., Unuma, A., Yoshida, K., Nakatani-Enomoto, S., Hatanaka, Y., Sakurai, Y., Shiio, Y., Kaida, K., Kubota, A., Toda, T., Shimizu, J. Tags: Autoimmune diseases, Muscle disease Article Source Type: research

Juvenile dermatomyositis with IgA nephropathy: case-based review
We report a 10-year-old boy with juvenile dermatomyositis and IgA nephropathy. Child responded dramatically to the conventional therapy with steroids and methotrexate for the primary disease, and did not require any additional treatment for his renal disease. Child ’s primary disease is in remission and has normal urinalysis with normal renal function at 6-month follow-up. We reviewed the literature and found 11 cases of IIMs with renal involvement. Four patients (one JDM, two polymyositis, and one dermatomyositis) had IgA nephropathy out of which three pati ents responded to the conventional therapy of primary disease a...
Source: Rheumatology International - December 14, 2018 Category: Rheumatology Source Type: research

Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies
AbstractRecent studies have shown a high prevalence of dyslipidemia in patients with systemic autoimmune myopathies (SAM). However, little is known about the safety of the use of statins in these patients, and this gap in research motivated the accomplishment of the present study. In a retrospective cohort study conducted from 2004 to 2018, 250 patients with SAM were evaluated, and 24 patients had stable forms of SAM (16 dermatomyositis, 1 polymyositis and 7 antisynthetase syndrome) but had dyslipidemia and had received statins. Patients with clinically amyopathic dermatomyositis, immune-mediated necrotizing myopathy, derm...
Source: Rheumatology International - December 5, 2018 Category: Rheumatology Source Type: research

Autoimmune Myopathies: Updates on Evaluation and Treatment
AbstractThe major forms of autoimmune myopathies include dermatomyositis (DM), polymyositis (PM), myositis associated with antisynthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM). While each of these conditions has unique clinical and histopathological features, they all share an immune-mediated component. These conditions can occur in isolation or can be associated with systemic malignancies or connective tissue disorders (overlap syndromes). As more has been learned about these conditions, it has become clear that traditional classification schemes do not adequately g...
Source: Neurotherapeutics - October 16, 2018 Category: Neurology Source Type: research

Neuromuscular manifestations of primary biliary cholangitis: two case reports and literature review.
We report two cases of patients with the diagnosis of PBC with neurologic complications: one case with asymptomatic PBC and myopathy and another one with demyelinating neuropathy. Neurologic diseases in patients with PBC have been described mainly as case reports. The co-occurrence of both entities suggests the possible existence of a common pathogenic mechanism but the real etiopathogeny is still unknown. PMID: 30641539 [PubMed - in process]
Source: Acta Reumatologica Portuguesa - October 1, 2018 Category: Rheumatology Authors: Brites L, Ribeiro J, Luis M, Santiago M, Negrão L, Duarte C Tags: Acta Reumatol Port Source Type: research

Inflammatory myopathies
Idiopathic inflammatory myopathy is a group of acquired myopathies with subacute onset of limb muscle weakness. Here we describe the clinical and laboratory characteristics of 161 Chinese patients with inflammatory myopathies in Xiangya hospital from 2011 to 2017. Clinical and laboratory data were collected. Immunoassay for detection of myositis-specific antibodies was performed in 55 cases. Our cohort consisted of 70 patients with polymyositis (PM), 81 dermatomyositis (DM), 7 immune-mediated necrotizing myopathy (IMNM) and 3 inclusion body myositis (IBM).
Source: Neuromuscular Disorders - September 6, 2018 Category: Neurology Authors: Y.B. Luo, H. Duan, Q. Li, F. Bi Source Type: research

Autoantibody to transcriptional intermediary factor-1 β as myositis-specific antibody: clinical correlation with CADM or DM with mild myopathy.
CONCLUSION: Seven patients were confirmed to have anti-TIF-1β antibody without any other MSAs, including TIF-1α/γ antibodies, and six of them were diagnosed with DM. We suggest that anti-TIF-1β antibody is one of the MSAs, and that it is associated with clinically amyopathic DM or DM with mild myopathy. This article is protected by copyright. All rights reserved. PMID: 30120913 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - August 18, 2018 Category: Dermatology Authors: Ueda-Hayakawa I, Hamaguchi Y, Okiyama N, Motegi SI, Yamaoka T, Miyake S, Higashi A, Okamoto H, Takehara K, Fujimoto M Tags: Br J Dermatol Source Type: research

Classification and management of adult inflammatory myopathies
Publication date: September 2018Source: The Lancet Neurology, Volume 17, Issue 9Author(s): Albert Selva-O'Callaghan, Iago Pinal-Fernandez, Ernesto Trallero-Araguás, José César Milisenda, Josep Maria Grau-Junyent, Andrew L MammenSummaryInflammatory myopathies, collectively known as myositis, are heterogeneous disorders characterised by muscle inflammation, and frequently accompanied by extramuscular manifestations that affect the skin, lung, and joints. Patients with inflammatory myopathies were previously classified as having dermatomyositis if characteristic rashes accompanied the muscle involvement, and as having poly...
Source: The Lancet Neurology - August 15, 2018 Category: Neurology Source Type: research

Immune checkpoint failures in inflammatory myopathies: An overview
Publication date: Available online 6 June 2018Source: Autoimmunity ReviewsAuthor(s): Sandrine Herbelet, Jan L. De BleeckerAbstractDermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), immune mediated necrotizing myopathy (IMNM) and overlap myositis (OM) are classified as inflammatory myopathies (IM) with involvement of autoimmune features such as autoreactive lymphocytes and autoantibodies. Autoimmunity can be defined as a loss in self-tolerance and attack of autoantigens by the immune system. Self-tolerance is achieved by a group of immune mechanisms occurring in central and periphal lymphoid organs and ...
Source: Autoimmunity Reviews - July 10, 2018 Category: Allergy & Immunology Source Type: research

Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study
We report the first cohort study of PO CYC use in IIM patients with severe , treatment refractory disease. Further trials are needed to verify these results as well as to evaluate long-term safety outcomes.
Source: Clinical Rheumatology - July 3, 2018 Category: Rheumatology Source Type: research

Immune checkpoint failures in inflammatory myopathies: An overview
Publication date: Available online 6 June 2018 Source:Autoimmunity Reviews Author(s): Sandrine Herbelet, Jan L. De Bleecker Dermatomyositis (DM), polymyositis (PM), inclusion bosy myositis (IBM), immune mediated necrotizing myopathy (IMNM) and overlap myositis (OM) are classified as inflammatory myopathies (IM) with involvement of autoimmune features such as autoreactive lymphocytes and autoantibodies. Autoimmunity can be defined as a loss in self-tolerance and attack of autoantigens by the immune system. Self-tolerance is achieved by a group of immune mechanisms occurring in central and periphal lymphoid organs and tissu...
Source: Autoimmunity Reviews - June 7, 2018 Category: Allergy & Immunology Source Type: research